• Taysha Gene Therapies granted a new employee 144,000 RSUs plus stock options for 92,400 shares under its 2023 Inducement Plan.
• RSUs vest in four equal annual installments starting on the first anniversary, subject to continued service.
• Options carry a $5.78 exercise price, a 10-year term, vesting over four years with 25% after one year.
• Remaining 75% of the options vest in equal monthly installments over the next 36 months, subject to continued service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070800PRIMZONEFULLFEED9804842) on August 07, 2026, and is solely responsible for the information contained therein.